ATE245032T1 - Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen - Google Patents

Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen

Info

Publication number
ATE245032T1
ATE245032T1 AT01910800T AT01910800T ATE245032T1 AT E245032 T1 ATE245032 T1 AT E245032T1 AT 01910800 T AT01910800 T AT 01910800T AT 01910800 T AT01910800 T AT 01910800T AT E245032 T1 ATE245032 T1 AT E245032T1
Authority
AT
Austria
Prior art keywords
neurotoxins
medications
thyroid disorders
treat thyroid
treat
Prior art date
Application number
AT01910800T
Other languages
German (de)
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE245032T1 publication Critical patent/ATE245032T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01910800T 2000-02-15 2001-02-15 Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen ATE245032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/504,538 US6524580B1 (en) 2000-02-15 2000-02-15 Method for treating thyroid disorders
PCT/US2001/004990 WO2001060396A2 (en) 2000-02-15 2001-02-15 Method for treating thyroid disorders

Publications (1)

Publication Number Publication Date
ATE245032T1 true ATE245032T1 (de) 2003-08-15

Family

ID=24006701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910800T ATE245032T1 (de) 2000-02-15 2001-02-15 Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen

Country Status (10)

Country Link
US (6) US6524580B1 (https=)
EP (1) EP1253933B1 (https=)
JP (2) JP2003530320A (https=)
AR (1) AR027442A1 (https=)
AT (1) ATE245032T1 (https=)
AU (1) AU2001238369A1 (https=)
DE (1) DE60100473T2 (https=)
ES (1) ES2199209T3 (https=)
TW (1) TWI283177B (https=)
WO (1) WO2001060396A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US8563257B2 (en) * 2000-03-30 2013-10-22 Diagnostic Hybrids, Inc. Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US8293879B2 (en) 2000-03-30 2012-10-23 Diagnostic Hybrids, Inc. Methods of using chimeric receptors to identify autoimmune disease
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7178059B2 (en) * 2003-05-07 2007-02-13 Egenera, Inc. Disaster recovery for processing resources using configurable deployment platform
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8137924B2 (en) * 2003-12-19 2012-03-20 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
JP5826450B2 (ja) 2005-07-22 2015-12-02 ザ ファウンドリー， エルエルシー 治療薬の送達のためのシステムおよび方法
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US7708699B2 (en) * 2005-11-18 2010-05-04 Daag International, Inc. Reflexometry and hormone function
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
RU2446791C2 (ru) * 2009-06-18 2012-04-10 Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" Способ этаноловой склеротерапии кистозно-трансформированных узлов щитовидной железы
AU2010315396B2 (en) 2009-10-27 2016-05-05 Nuvaira, Inc Delivery devices with coolable energy emitting assemblies
JP6000851B2 (ja) 2009-11-11 2016-10-05 ホライラ， インコーポレイテッド 組織治療および狭窄制御のためのシステム、装置、および方法
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9011323B2 (en) * 2010-10-08 2015-04-21 Invuity, Inc. Method and apparatus for soft tissue retraction
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
AU2022252296A1 (en) 2021-03-30 2023-09-21 Tulavi Therapeutics, Inc. Methods and compositions for the ablation of nerves
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5786348A (en) * 1991-01-08 1998-07-28 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
ES2107051T3 (es) 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6007843A (en) 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP1011695B2 (en) 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6022554A (en) 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6432723B1 (en) * 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6432623B1 (en) * 2001-04-27 2002-08-13 Eastman Kodak Company Method for processing a photographic element comprising a simultaneously coated protective overcoat

Also Published As

Publication number Publication date
ES2199209T3 (es) 2004-02-16
TWI283177B (en) 2007-07-01
AR027442A1 (es) 2003-03-26
US6743424B1 (en) 2004-06-01
US6524580B1 (en) 2003-02-25
JP2012207030A (ja) 2012-10-25
WO2001060396A2 (en) 2001-08-23
WO2001060396A3 (en) 2002-03-14
AU2001238369A1 (en) 2001-08-27
US6447785B1 (en) 2002-09-10
US6716427B1 (en) 2004-04-06
JP2003530320A (ja) 2003-10-14
US6740321B1 (en) 2004-05-25
US6585970B1 (en) 2003-07-01
DE60100473T2 (de) 2004-04-15
DE60100473D1 (de) 2003-08-21
EP1253933A2 (en) 2002-11-06
EP1253933B1 (en) 2003-07-16

Similar Documents

Publication Publication Date Title
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
ATE257013T1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
DE60232400D1 (de) Mittel zur linderung von hautreizungen
ATE338557T1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE50107445D1 (de) Verwendung von polyesteramiden zur stabilisierung von asphaltenen in rohöl
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60015516D1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
PL357674A1 (pl) Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią
EE200100514A (et) LFA-1 ICAM-idega seondumise inhibiitorid ja nendekasutamine
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
ATE304854T1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
ATE465728T1 (de) Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
WO2002004521A3 (en) Proteins with integrin-like activity
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE69922873D1 (de) Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
ATE473002T1 (de) Zusammensetzungen zur vorbeugung von geschwüren in pferden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties